Clinical Trial Detail

NCT ID NCT03718767
Title Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

malignant glioma

Therapies

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST